ANTONARELLI, GABRIELE

ANTONARELLI, GABRIELE  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 19 di 19 (tempo di esecuzione: 0.008 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 2022 Mazzarella, LGiugliano, FNicolo', ECrimini, EUliano, JCorti, CRepetto, MAntonarelli, GAscione, LVivanet, GCriscitiello, CCurigliano, G + Article (author) -
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 2023 Tarantino, PaoloAntonarelli, GabrieleBoscolo Bielo, LucaCrimini, EdoardoGiugliano, FedericaZagami, PaolaCorti, ChiaraTrapani, DarioCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 2022 Tarantino, PaoloAntonarelli, GabrieleBoscolo Bielo, LucaMarra, AntonioCrimini, EdoardoGiugliano, FedericaZagami, PaolaCorti, ChiaraTrapani, DarioMorganti, StefaniaCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group 2022 Antonarelli, GabrieleCorti, ChiaraPerrino, MatteoManglaviti, SaraCurigliano, GiuseppeConforti, Fabio + Article (author) -
COVID-19 related risk in patients enrolled in early-phase clinical trials 2021 Morganti, SCorti, CVivanet, GCrimini, EAntonarelli, GCurigliano, G + Article (author) -
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? 2022 Antonarelli G.Curigliano G. + Article (author) -
Harmonizing PD-L1 testing in metastatic triple negative breast cancer 2022 Giugliano F.Antonarelli G.Curigliano G. + Article (author) -
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? 2022 Corti, ChiaraAntonarelli, GabrieleValenza, CarmineCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 2021 Giugliano, FCrimini, EUliano, JCorti, CRepetto, MAntonarelli, GVivanet, GCriscitiello, CCurigliano, G + Article (author) -
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development 2022 Antonarelli G.Curigliano G. + Article (author) -
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 2023 Antonarelli, GCorti, CTarantino, PZagami, PMarra, ATrapani, DCurigliano, G + Article (author) -
Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies 2021 Antonarelli G.Giugliano F.Corti C.Repetto M.Curigliano G. + Article (author) -
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 2021 Trillo Aliaga P.Trapani D.Crimini E.Antonarelli G.Vivanet G.Morganti S.Corti C.Criscitiello C.Curigliano G. + Article (author) -
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review 2022 Corti C.Antonarelli G.Curigliano G. + Article (author) -
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 2021 Crimini E.Corti C.Repetto M.Giugliano F.Antonarelli G.Zagami P.Morganti S.Uliano J.Curigliano G. + Article (author) -
Targeting brain metastases in breast cancer 2022 Corti C.Antonarelli G.Criscitiello C.Curigliano G. + Article (author) -
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 2022 Mazzarella LCrimini EUliano JCorti CTrillo Aliaga PRepetto MAntonarelli GCriscitiello CCurigliano G. + Article (author) -
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers 2023 P. ZagamiG. AntonarelliG. CuriglianoF. Conforti + Article (author) -
Therapeutic Cancer Vaccines Revamping: Technology Advancements and Pitfalls 2021 Antonarelli, GCorti, CCurigliano, G + Article (author) -